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Abstract
The discovery of charged molecules being 
able to cross the mitochondrial membrane has 
prompted many scholars to exploit this idea to 
find a way of preventing or slowing down aging. 
In this paper, we will focus on mitochondria-
targeted antioxidants, which are cationic 
derivatives of plastoquinone, and in particular 
on the mitochondria-targeted antioxidant therapy 
of neurodegenerative diseases. It is well known 
that the accumulation of amyloid-β peptide (Aβ) 
in mitochondria and its related mitochondrial 
dysfunction are critical signatures of Alzheimer’
s disease (AD). In another neurodegenerative 
disease, Parkinson’s disease (PD), the loss of 
dopaminergic neurons in the substantia nigra 
and the production of Lewy bodies are among 
their pathological features. Pathogenesis of 
Parkinson’s disease and Alzheimer’s disease 
has been frequently linked to mitochondrial 
dysfunction and oxidative stress. Recent studies 
show that MitoQ, a mitochondria-targeted 
antioxidant, may possess therapeutic potential 
for Aβ-related and oxidative stress-associated 
neurodegenerative diseases, especially AD. 
Although MitoQ has been developed to the stage 
of clinical trials in PD, its true clinical effect 
still need further verification. This review aims 
to discuss the role of mitochondrial pathology 
in neurodegenerative diseases, as well as the 
recent development of mitochondrial targeted 
antioxidants as a potential treatment for these 
diseases by removing excess oxygen free 
radicals and inhibiting lipid peroxidation in order 
to improve mitochondrial function.
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Introduction
Currently there are three pharmacological therapy 
approaches for mitochondrial disorders [1]: the first 
approach is to engineer compounds which selectively 
target to mitochondria; the second one is to design 
compounds that are not targeted to mitochondria but 
act on them based on their binding to specific targets; 
and the third one is to use compounds located outside 
the mitochondria but that ultimately affect the function 
of mitochondria [2]. Mitochondria-targeted antioxidants, 
10-(6’-plastoquinonyl) decyl-triphenylphosphonium (SkQ1) 
and its analog plastoquinonyl decylrhodamine 19 (SkQR1), 
have been proved to slow down or even reverse the effects 
of aging [3, 4, 5]. Another important antioxidant is MitoQ, 
a synthetic analog of coenzyme Q10. As a mitochondria-
targeted antioxidant, MitoQ can selectively accumulate in 
mitochondrial and remove excess oxygen free radicals, 
prevent lipid peroxidation and protect mitochondria 
and cell membranes against oxidative stress. An ever-
increasing number of studies suggest that MitoQ possess 
some positive effect in treating neurological diseases with 
mitochondrial dysfunction and oxidative stress as main 
pathological features. In particular, the pathogenesis of 
neurodegenerative diseases, Alzheimer's and Parkinson’
s disease, is very complex because of the involvement a 
vast number of factors. Since mitochondrial dysfunction 
and oxidative stress are among the most relevant factors [6] 
and they happen in the early onset of neurodegenerative 
diseases, they can be considered as essential and 
potential therapeutic targets for the early treatment of the 
disease.
Neurodegenerative diseases
Alzheimer’s disease is a worldwide neurodegenerative 
disease typically correlated with aging. About 36.5 
million people around the world are affected and this 
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number will rapidly increase in the future, especially in 
China, India, and Latin America [7]. In addition, young-
onset cases have more frequently been reported and 
to date there is no effective treatment that can be used 
as a cure. This disease is characterized by wide spread 
synaptic damage and neuronal death with accumulation 
of intracellular neurofibrillary tangles and extracellular 
amyloid plaques of mainly Aβ [8]. In the early stages of 
AD, mitochondrial dysfunction induced oxidative stress 
can result in macromolecule damage, mainly lead by 
hydroxyl radicals [9]. The different aspects of the disease 
have been revealed through the studies on Alzheimer 
cells and transgenic mouse models which allow the 
direct observation of the pathogenic mechanisms of AD, 
especially the interaction between Aβ and mitochondria. 
Mitochondria are not only the target for amyloid precursor 
protein (AβPP) that releases and accumulates Aβ in the 
mitochondrial import channels, but also for Aβ which 
interacts with different proteins in the mitochondria, 
affecting normal mitochondrial function [10]. In humans, 
AβPP is present in many cellular structures like plasma 
membrane and many organelles such as endoplasmic 
reticulum, Golgi apparatus, as well as mitochondria. AβPP 
produces Aβ, a peptide of 39-43 amino acids in length, 
via the action of a β-secretase and then a γ-secretase 
enzyme [11]. Mitochondria, endosomes, Golgi and 
endoplasmic reticulum have been described as the major 
targets of Aβ. In mitochondria, Aβ can induce dysfunction 
of mitochondrial Ca2+channels [12] and affect the activity 
of mitochondrial. Indeed, pyruvate dehydrogenase and 
α-ketoglutarate dehydrogenase can be altered decreasing 
NADH reduction, as well as the electron transport chain 
(ETC) enzyme complex IV, causing a reduction in the 
proton pumping across the inner mitochondrial membrane 
and hence altering the mitochondrial membrane potential 
[13]. The effect on complex V activity results in a decrease 
in ATP production along with an increasing in reactive 
oxygen species (ROS) production (Figure 1). Normally, 
excess ROS is removed by the antioxidant defense 
system, but oxidative stress may lead to a series of 
injuries due to an imbalance of antioxidant and prooxidant 
homeostasis, such as the damage of nucleic acids, 
proteins, and lipids [14]. On the other hand, excessive 
ROS negatively regulates presequence P (PreP) activity, 
hindering the normal degradation of Aβ and leading to an 
increase in Aβ content in mitochondria. Additionally, ROS 
induces mitochondrial peroxidation of macromolecules 
such as mitochondrial DNA and lipids, and it also damages 
the mitochondrial function by interfering with the fusion and 
fission processes of mitochondria, leading to mitochondrial 
fragmentation [15] and increased mitochondrial DNA 
mutations [10]. Besides, excess production of ROS 
also induces synaptic dysfunction by increasing tau 
hyperphosphorylation and neurofibrillary tangle formation, 
eventually leading to synaptic failure. There is wide 
evidence that oxidative stress plays an essential role in 
the pathological process of AD induced by Aβ. Therefore, 
it sounds to work on the elimination of free radicals and 
prevent them from being produced as a therapy for AD. In 
fact, many studies have been carried out with this scope. 
In one study, a mitochondria-targeted antioxidant, MitoQ, 
has been used to reverse the cognitive decline and to 
prevent early neuropathology in a transgenic mouse model 
of AD by acting against the attack of Aβ-induced toxicity 
and oxidative stress [16]. 
Parkinson’s disease is the second prevalent progressive 
neurodegenerative disease that affects about 2% of 
people over the age of 60 [17]. One of the pathological 
characteristics of PD is the loss of dopaminergic neurons 
in the substantia nigra pars compacta that causes motor 
symptoms. The other feature is the dopamine depletion 
in the striatum. PD is also associated with the presence 
of Lewy bodies in surviving dopaminergic neurons 
[18]. To date, the treatment of PD remains only on the 
surface, and current therapies cannot effectively slow or 
prevent the pathologic progression of the disease [19]. 
Although extensive studies have been carried out on 
PD, its precise etiology remains largely unknown despite 
some pathological mechanisms, such as mitochondrial 
dysfunction, oxidative stress and the ubiquitin-proteasome 
system disruption, as well as neuroinflammation have 
been brought forward. Under these assumptions, oxidative 
stress and mitochondrial dysfunction could be considered 
as reasonable candidates. In fact, mitochondrial DNA 
mutations have been shown to play a significant role in the 
death of dopaminergic neurons [20] and a great wealth 
of evidence suggests that mitochondrial dysfunction 
plays a vital role in the course of PD pathogenesis. One 
of the most significant research lines is the study of 
MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydrodropyrid
ine), a Parkinsonian toxin which selectively depressed 
mitochondrial complex I inducing Parkinsonian syndromes 
[21].  Another toxic metabol i te,  or iginated by the 
action of monoamine oxidase on MPTP is 1-methyl-4-
phenylpyridinium (MPP+) [22]. It is transported into the 
dopaminergic neurons by the dopamine transporter and 
accumulates in the mitochondria, causing adenosine 
triphosphate depletion through inhibition of complex I 
activity, changes in mitochondrial membrane potential, 
increases in the production of ROS and finally leads to 
apoptotic cell death [23]. Similarly, other complex I inhibitors 
for like rotenone, fenpyroximate and trichloroethylene also 
lead to dopaminergic neurodegeneration in many research 
models include human, all indicating mitochondrial 
dysfunction plays an important role in PD pathomechanism 
[24]. These toxic substances affect the normal functioning 
of mitochondria, result in a decreasing of function of 
electron transport chain [25] and mitochondrial mobility 
[26]. Furthermore, they can also induce an increase of the 
mitochondrial permeability transition and the production of 
ROS, as well as an increase in the activity of nitric oxide 
synthase. In PD patients, the function of complex I is 
impaired in the substantia nigra. The change in complex 
I structure is due to the absence of apoptosis inducing 
factors which does not cause neurodegeneration due 
to the loss of dopaminergic neurons, but makes the 
dopaminergic neurons more susceptible to neurotoxins 
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[27].
Pathological mutations in many genes such as Parkin, 
α-synuclein, LRRK2 and DJ-1, PINK1, directly or indirectly 
demonstrate that mitochondrial dysfunction plays a role in 
PD patients [17]. Parkin, the E3 ubiquitin ligase, has been 
associated with the function of the respiratory chain. A 
lack of Parkin in mice and flies, for instance, would show a 
reduction in the level of proteins involved in mitochondrial 
function, reduced activity of complex I and complex IV of 
the electron transport chain and disrupted mitochondrial 
integrity [28]. Mutations in Parkin cause autosomal 
recessive juvenile PD. Similarly, mutations in PINK1 
(PTEN-induced putative kinase 1) can also lead to an 
autosomal recessive form of PD, and such form is familial 
and early-onset. In cell culture models of Parkinsonism, 
mutationsin PINK1 result in decreasing mitochondrial 
respiratory chain function, leading to reduced ATP 
synthesis and the increase of α-synuclein aggregation [29].
PINK1 localizes to mitochondria via a multisubunit complex 
that includes the outer membrane protein TOM40 and 
the inner membrane protein TIM23. Upon translocation, 
it is cleaved by MPP and PARL proteases leading to 
its degradation. However, under stress conditions or in 
damaged mitochondria, it cannot be cleaved and stabilizes 
in the outer membrane leading to autophosphorilation and 
serine phosphorylation of ubiquitin and Parkin, promoting 
ubiquitination of the mitochondrial outer membrane protein 
to trigger selective mitochondrial autophagy (Figure 2) 
[30-32]. Parkin and PINK1 knockouts in Drosophila, has 
also shown that they are on same functional pathway, and 
that PINK1 has the ability to upregulate Parkin [30]. Thus, 
pathological changes in Parkin and PINK-1 disrupt normal 
mitochondrial function and well-balanced mitophagy. 
The mutation of DJ-1 lead to a rare and early-onset form 
of Parkinsonism, such form of PD is also autosomal 
recessive. Human who carry this gene mutation exhibit 
damage to the oxidative respiratory chain in mitochondria, 
decrease membrane potential, and increased levels of 
ROS in mitochondria, as well as altered regular mitophagy 
[33]. 
Figure 1. The generation and influence of Aβ. AβPP is synthesized in the endoplasmic reticulum (ER) and then directed to Golgi network, 
the cell surface or to mitochondria. In the plasma membrane, the apolipoprotein receptor LRP1 forms a complex with AβPP, together 
with other plasma membrane enzymes, such as the β-secretase BACE and the γ-secretase presenilin (PS), inducing the internalization 
of the amyloid precursor protein. AβPP produces Aβ, a 39-43 amino acid polypeptidevia the activity of β-secretase and then γ-secretase 
enzymes [11]. Aβ originates in the endosome (En), Golgi and ER, and it is especially present in Golgi or in late endosomes following the 
reuptake from the cell surface. Aβ enters into the mitochondrial matrix through TOM and TIM or is derived from mitochondria-associated 
AβPP metabolism. In mitochondria, Aβ can affect several enzymes inducing NADH reduction and the ETC enzyme complex IV, causing 
a reduction in the amount of protons and resulting in a decrease in ATP, which increases ROS production. Excessive amounts of ROS 
leads to lipid peroxidation and negatively regulates presequence P (PITM1/PreP) activity, hindering the normal degradation of Aβ and 
leading to an increase in Aβ content in mitochondria.
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To date, no specific drug has been developed to slow 
down the progression of PD. Consequently, new therapies 
are urgently needed. Coenzyme Q, a vital antioxidant 
in the respiratory chain, is located in the lipid layer of 
mitochondria. Coenzyme Q10 possess neuroprotective 
effects that could protect against mitochondrial toxins, 
for example, MPTP. Although this antioxidant has been 
shown to be safe and patient tolerant, it has not shown 
any clinical value in the phase III of clinical trials that have 
already been carried out [34]. MitoQ is another powerful 
mitochondria-targeted antioxidant, which accumulates 
in the mitochondria and resists the damage induced by 
oxidative stress. However, a study using MitoQ did not 
revealed a slowdown in the progression of PD [35].
Mitochondria-targeted antioxidant therapy
The two most common approaches for the use of small 
molecules in vivo as mitochondrial targeted antioxidants 
are: conjugation to a lipophilic cation or absorbtion into 
mitochondria-targeted peptides. 
Lipophil ic cations can readily pass through the 
phospholipid bilayer, such as plasma membrane or the 
mitochondrial membrane, due to the effective distribution 
of charge cations in a large and hydrophobic surface that 
reduces their activation energy and enables their passage 
across the membrane [36]. These lipophilic cations can 
cross lipid bilayers without the need of ionophores or 
carrier proteins and accumulate in the mitochondrial matrix 
thanks to the negative-inside mitochondrial membrane 
potential. Triphenylphosphonium (TPP) cation is the most 
widely used lipophilic cation to transfer antioxidants into 
mitochondria. It consists of an intermediate positive charge 
of phosphorus and a surrounding hydrophobic surface. 
Therefore, TPP can quickly cross the phospholipid 
bilayer and retain the positive charge. Such positive 
charge is used to drive TPP cation first into the cell and 
subsequently into the mitochondrial matrix. The plasma 
membrane potential is 30-60 mV (negative inside), 
which favors a 10-fold higher concentration of TPP in 
the cytoplasm than outside the cell. Similarly, the much 
greater mitochondrial membrane potential, ~140-160mV, 
strengthens the reallocation of lipophilic cations from 
Figure 2. The PINK-1–Parkin pathway. In the normal conditions, PINK1 is imported to the mitochondria through TOM and TIM complex, 
on the outer mitochondrial membrane (OMM) and the inner mitochondrial membrane (IMM), respectively. After entry, PINK-1 is 
sequentially cleaved by inner mitochondrial membrane proteases MPP and PARL, between amino acids 103 and 104. The remaining 
N-terminal fragment is then degraded via the N-end rule pathway in the cytosol. However, when mitochondria are damaged or the TIM 
complex is non–functional due to mitochondrial depolarization, PINK1 processing by MPP and PARL is restrained because of lack of 
import into the inner membrane. Instead, PINK1 accumulates on the OMM bound to the TOM complex, where it phosphorylates ubiquitin 
at Ser65. This stimulates the recruitment of cytosolic Parkin to the mitochondrial surface via the direct binding to phospho-ubiquitin 
chains. Parkin is then also phosphorylated by PINK1 and activates it.
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the intracellular space into the mitochondria, leading to 
~200-400 fold accumulation of TPP in the mitochondrial 
matrix [37]. Based on this principle, researchers targeted 
many antioxidants to mitochondria by conjugation to the 
TPP cation, including MitoQ.
MitoQ is a mitochondria-targeted ubiquinol, it consists of 
an ubiquinone moiety covalently attached to a TPP moiety 
by a ten-carbon aliphatic carbon chain [38]. The TPP 
moiety on MitoQ can cross the plasma membrane due 
to the plasma membrane potential and then accumulate 
hundreds-fold in the mitochondrial matrix compared 
to cytosol due to its greater membrane potential [16]. 
Once MitoQ accumulates in the matrix side of the inner 
membrane, it persistently removes peroxyl radicals, 
peroxynitrite, superoxide, prevents lipid peroxidation as 
well as mitochondrial injury [39, 40]. After detoxifying 
oxidants, the ubiquinol is oxidized to ubiquinone and 
recycled by the electron transport chain complex II [41, 
42]. Consequently, this directionally accumulates MitoQ in 
the mitochondrial matrix where it is continually recycled, 
making this targeted-antioxidant hundreds-fold more 
powerful than other antioxidants [38]. On the other hand, 
the ubiquinol moiety of MitoQ can also react directly with 
superoxide and protect against peroxynitrite [43]. However, 
in some cases, due to the redox cycle of quinone, it may 
be pro-oxidant and pro-apoptotic and generate superoxide 
[44]. MitoQ has been shown to possess a protective effect 
in a large number of animal models of diseases related 
to oxidative stress such as neurodegenerative disease 
(including Alzheimer's disease, Parkinson's disease etc.) 
[16, 20], ischemia-reperfusion [45], type 2 diabetic [46] and 
hypertension [47].
To evaluate the potential effect of MitoQ on Alzheimer’
s disease, different mouse models were analyzed and 
it has been reported that MitoQ was able to prevent the 
accumulation of Aβ, inhibit Aβ induced oxidative stress 
and reverse the reduction of synapses and early cognitive 
decline. In particular, MitoQ protected neurons against Aβ 
in a transgenic mouse model of AD and diminished the 
neurological deficits in the mice [16]. In cultured mouse 
sympathetic neurons, deprivation of nerve growth factor 
induced cell death but MitoQ treatment blocked apoptosis 
by preventing increased mitochondria-derived ROS and 
subsequent cytochrome c release, caspase activation, 
and mitochondrial damage by scavenging mitochondrial 
superoxide [48]. Several studies have shown that MitoQ 
can not only increase life span, postpone Aβ induced 
paralysis, but also improve mitochondrial lipid cardiolipin 
depletion, as well as protect the ETC enzymes complex 
IV and complex I [49]. In SH-SY5Y cells, it could 
effectively inhibit mitochondrial fragmentation caused 
by 6-hydroxydopamine [50]. In another study, MitoQ 
effectively inhibited neurotoxicity induced by both MPP+- 
and MPTP in cell cultures and in a preclinical PD mouse 
model [51]. MitoQ inhibited the decrease in dopamine 
and tyrosine hydroxylase levels, as well as the loss of 
mitochondrial membrane potential caused by MPP+. 
It could also alleviate the depletion of dopamine and 
its metabolites caused by MPTP toxicity. In PD animal 
models, MitoQ decreased caspase-3 activation which was 
induced by MPP+ and alleviated mitochondrial aconitase 
inactivation which was mediated by MPTP, maintaining 
normal operational tricarboxylic acid cycle, and decreasing 
oxidative damage [51]. In one study, a PD mouse model 
was treated with high levels of MitoQ for up to 28 weeks 
and showed no evidence of toxicity on whole-body 
physiology. This result indicated that mitochondria-targeted 
antioxidant, MitoQ, can be safely administered long-term 
in mice [52]. MitoQ has undergone phase I and II clinical 
trials in Hepatitis C virus patients and was proved to be an 
effective strategy, demonstrating the potential therapeutic 
efficacy of MitoQ in chronic liver diseases [53]. However, 
in another double-blind clinical trial of PD patients, it 
failed to demonstrate any benefit in slowing down the 
pathologic process of PD during 12 months [35]. A 
potential explanation for these conflicting results is that the 
extent of dopamine neurons damage has exceeded the 
neuroprotective effect of MitoQ. In general, approximately 
fifty percent of dopamine neurons have been lost by the 
time there is a clinical diagnosis of PD. Thus, it is possible 
that the treatment on the remaining neurons is no longer 
able toprevent the progression of the disease. Although the 
beneficial effects of MitoQ in PD have been proved both 
in vitro and in vivo, further detailed studies are needed 
to test and verify its potential for treatment. However, it is 
not only neurodegenerative diseases the targets of MitoQ 
therapies. In 2015, a new clinical trial aimed to study the 
effects of MitoQ on improving physiological functions 
including vascular, motor, and cognitive in middle aged 
and elderly people was registered on clinicaltrials.gov 
[54]. In a recent study on human skeletal muscle feed 
arteries from 44 subjects, it has been shown that MitoQ 
could reverse age-related endothelial vascular dysfunction 
[55]. Furthermore, MitoQ could reduce the severity of 
renal damage in renal is chemia-reperfusion injury in rat 
models [45]. All this suggest that mitochondrial targeted 
antioxidants, such as MitoQ can be applied as treatment to 
a wide variety of diseases.
Conclusion
In neurodegenerative diseases, the two main pathological 
markers are mitochondrial dysfunction and oxidative 
stress. In addition to these two hallmarks, there are other 
pathological features, such as excessive production of 
ROS, mitochondrial DNA mutations or impaired ATP 
synthesis. Mitochondrial dysfunction plays a central 
role in AD and PD, and can be an important target 
for treating these diseases. As a new therapeutic 
method, mitochondria-targeted antioxidants have good 
pharmacological effects in various animal and cell 
culture models. Among them, MitoQ has been the most 
extensively studied. In the phase II clinical trial on PD 
patients, its beneficial effect has not been proven though. 
This may be due to the fact that mitochondrial dysfunction 
may represent early stages of the pathological process 
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of the disease, while pharmacological effects are usually 
pursued at later stages of the disease after the clinical 
diagnosis. Mitochondrial dysfunction and oxidative stress 
can not only define these neurodegenerative diseases, 
but may also be a new therapeutic strategy and therefore 
a bigger effort should be made to push research forward 
before these diseases encroaching on more people.
Future outlook
So far, MitoQ, is the most studied mitochondrial-targeted 
antioxidant, which has already been used in human 
clinical trials. In human phase I clinical trials, MitoQ 
performed good pharmacokinetic characteristics when first 
administered to Parkinson patients to see if it could slow 
the progression of the disease [35]. Although mitochondrial 
targeted therapies inaugurated a new era in mitochondrial 
dysfunction, such procedure still has some unresolved 
limitations. First, these specific compounds are often 
required to be located in the mitochondrial matrix or the 
matrix-facing surface of the inner membrane. Second, 
these compounds are not yet targeted to specific organs 
and thus, they are commonly concentrated in organs with 
higher mitochondrial content. Moreover, mitochondria-
targeted antioxidant MitoQ, has been shown to be safe for 
humans but still requires further clinical trials. The field of 
therapeutic mitochondrial compounds has only just begun, 
and there are many diseases caused by mitochondrial 
damage such as ischemia/reperfusion injury, diabetes and 
metabolic syndrome already waiting for this technology 
to mature. However, different diseases have diverse 
pathological features, which in turn, means further and 
specific testing.
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